Tyra Posts Q3 Loss of $51.1M, $700.5M Cash Funds Dabogratinib Through 2030
TYRA sits 61% above its 52-week low of $13.83.
Summary
Tyra reported a $51.1 million third-quarter net loss on rising R&D spend, but holds $700.5 million in cash and securities that management says funds operations through 2030. The company also detailed dabogratinib progress, with a Phase 3 adjuvant study planned for 2027.
Key Events · Earnings and Guidance · TYRA
-
Q3 Net Loss Widens to $51.1M
Third-quarter 2026 net loss was $51.1 million, or $0.74 per share, versus $29.9 million a year earlier, on 69,082,673 weighted-average shares.
-
$700.5M Cash Funds Operations Through 2030
Cash, cash equivalents and marketable securities totaled $700.5 million at September 30, 2026, which management expects to fund planned operations through 2030.
-
R&D Spend Jumps on Dabogratinib Trials
R&D expense rose to $43.1 million from $25.5 million and G&A to $11.7 million from $7.5 million, driven by SURF302, SURF303 and BEACH301 trial activity plus headcount growth.
-
Phase 3 Adjuvant Study Planned for 2027
Tyra is preparing health-authority engagement on a Phase 3 adjuvant dabogratinib study, with initiation expected in 2027 subject to regulatory feedback; SURF302's 60 mg cohort is fully enrolled and a 70 mg cohort is enrolling.
Analysis · TYRA · Life Sciences
The balance sheet is the headline here: $700.5 million in cash and securities at September 30, 2026, which management says funds operations through 2030 — roughly four years of runway for a company burning about $51 million a quarter. That removes any near-term financing need and shifts the debate entirely to clinical execution. Spending is climbing fast to get there: R&D rose to $43.1 million from $25.5 million a year ago and G&A to $11.7 million from $7.5 million, pushing the quarterly net loss to $51.1 million from $29.9 million. The pipeline update matters as much as the P&L — SURF302's 60 mg cohort is fully enrolled with a 70 mg cohort now enrolling, and the company is preparing health-authority engagement for a Phase 3 adjuvant study it expects to start in 2027. In achondroplasia, the BEACH301 study cleared five dose levels and the safety committee authorized a sixth. The next hard data points are all slated for 2027: Phase 3 initiation, additional SURF302 ablative results, initial SURF303 LG-UTUC results, and BEACH301 sentinel-cohort results.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TYRA was trading at $22.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $13.83 to $40.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.